Retatrutide Cuts Liver Fat but Not Fibrosis in New MASH Mouse and Hamster Study

What Did This New Preclinical Study Investigate?

A study published in the journal Obesity in 2026 (Briand and colleagues) asked a question the human TRIUMPH programme has not yet directly tested: does retatrutide, Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist, improve not just liver fat but the fuller disease picture of MASH — metabolic dysfunction-associated steatohepatitis, the more advanced, inflamed and often-scarred form of fatty liver disease that sits beyond simple steatosis.[1] The paper, titled “Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models,” appears in Obesity volume 34, Supplement 1, pages 43–53.[1]

Retatrutide already has published human liver-fat data from a Phase 2a trial in people with metabolic dysfunction-associated steatotic liver disease (MASLD), covered in our retatrutide vs survodutide liver-fat comparison. That trial measured liver fat by imaging. This new paper is a separate, preclinical rodent study using diet-induced obese (DIO) mouse and hamster MASH models — animals fed high-fat, high-cholesterol and fructose-enriched diets to reproduce the steatosis-inflammation-fibrosis progression seen in human MASH — and it adds histopathological scoring, an endpoint the human retatrutide trials published so far have not reported. It is entirely separate from Lilly's Phase 3 TRIUMPH programme in human obesity, covered in our retatrutide research overview.

Velox Peptides supplies retatrutide as an HPLC-verified (≥99% purity) lyophilised reagent for in vitro research use only. View the product page →

How Was the Study Designed?

The mouse arm used a diet-induced obese (DIO) MASH model — C57BL/6 mice fed a high-fat, high-cholesterol diet designed to drive the full steatosis-to-fibrosis disease sequence — dosed with retatrutide for 5 weeks, with body weight, body composition, food and water intake, and liver histology tracked throughout.[1] A separate hamster arm used a diet-induced hyperlipidaemic model, fed a high-fat/high-cholesterol diet alongside 10% fructose-supplemented drinking water, a species researchers use because hamster cholesterol handling more closely resembles human lipoprotein metabolism than does the mouse's.[1]

Alongside body weight and composition, the team tracked hepatic triglyceride content, histopathological steatosis, inflammation and fibrosis scores, the HOMA-IR insulin-resistance index, plasma lipids, and — in the hamster arm — diet-preference behaviour between standard chow, the high-fat/cholesterol diet and fructose-supplemented water.[1]

What Happened to Body Weight and Metabolic Markers in Mice?

Over the 5-week protocol, retatrutide reduced body weight in DIO MASH mice by 31% relative to vehicle-treated controls (p<0.0001), alongside significant reductions in both fat mass and lean mass and in food and water intake during the first days of treatment; energy expenditure was not significantly altered.[1] The treated mice also showed a marked improvement in the HOMA-IR insulin-resistance index, along with reductions in plasma fatty acids, triglycerides and total cholesterol.[1]

These weight, composition and insulin-sensitivity effects are broadly consistent with retatrutide's mechanism as a triple incretin-receptor agonist and echo patterns seen in other rodent metabolic studies of the compound, including the MC4R-knockout mouse comparison covered separately on Velox. This is rodent dosing in a diet-induced model, not a clinical trial, and none of these figures describe any human outcome.

Did Retatrutide Improve Liver Fibrosis in the MASH Model?

This is the study's most nuanced finding. Hepatic triglyceride content — the fat component of MASH — fell by roughly 50% in both the mouse and hamster models (p<0.01), and the hepatic steatosis histology score improved.[1] But MASH is defined by three components together: steatosis (fat), inflammation, and fibrosis (scarring). On the histopathological scoring used in this study, retatrutide did not produce a statistically significant reduction in inflammation or fibrosis scores over the 5-week mouse protocol.[1]

The authors' own framing is that retatrutide delivers multiple metabolic benefits in these models without those benefits necessarily reaching the histological fibrosis endpoint within the timeframe tested. That is a meaningfully different, more limited claim than “reverses MASH,” and researchers citing this paper should preserve that distinction rather than round it up.

What Did the Hamster Model Add?

Hamsters were maintained on a choice-feeding paradigm — simultaneous access to standard chow, a high-fat/high-cholesterol diet, and 10%-fructose drinking water — designed to model diet-driven metabolic disease under conditions closer to voluntary human dietary choice than forced single-diet mouse protocols. Retatrutide shifted this behaviour: treated hamsters increased their intake of standard chow while decreasing intake of the high-fat/cholesterol diet and the fructose-supplemented water.[1] As in the mouse arm, hepatic triglyceride content fell by around 50% in hamsters, again without a matching improvement in fibrosis or inflammation histology.[1]

The diet-preference shift is a behavioural finding specific to rodents housed with a choice of feeds; it describes food-selection behaviour in a controlled hamster paradigm and carries no implication for human appetite, food choice, or eating behaviour of any kind.

How Does This Compare With Retatrutide's Human Liver-Fat Trial Data?

What Are the Limitations Researchers Should Note?

Several caveats matter for anyone citing this dataset. First, this is a single peer-reviewed study across two rodent species, not a replicated finding across independent cohorts. Second, the 5-week mouse dosing window is short relative to the timescale over which fibrosis typically develops or resolves; a longer treatment period might, in principle, produce a different histological result, but that has not been tested. Third, mouse and hamster dosing regimens in diet-induced disease models are species-specific research protocols with no established translation to human dosing; nothing in this paper should be read as dosing guidance of any kind. Fourth, diet-induced obese models reproduce diet-driven MASH but do not capture every driver of human MASH, including genetic and metabolic factors that vary between patients.

None of these findings constitute evidence of any weight-loss, liver, or metabolic effect of retatrutide in humans, and they do not describe any property of Velox Peptides' research-grade retatrutide product, which is supplied strictly for in vitro laboratory use and carries no therapeutic or health-benefit claims.

Velox Peptides Supply Information

Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions